| Cat. No. |
Product Name |
Information |
| PC-47502 |
Taspoglutide
GLP-1 agonist
|
Taspoglutide (ITM-077, R-1583, BIM-51077) is a glucagon-like peptide-1(GLP-1) agonist with EC50 of 0.06 nM, shows potential for treatment of type 2 diabetes. |
| PC-47501 |
Lixisenatide
GLP-1 agonist
|
Lixisenatide (ZP10A) is a peptide glucagon-like peptide 1 (GLP-1) receptor agonist. |
| PC-45831 |
MK-0893
Glucagon receptor antagonist
|
A potent, selective, reversible and competitive antagonist of glucagon receptor with high binding affinity (IC(=50=6.6 nM) and functional cAMP activity (IC50=15.7 nM). |
| PC-45745 |
Adomeglivant
GCGR antagonist
|
Adomeglivant (LY-2409021) is a potent, selective, orally active, small-molecule antagonist of human glucagon receptor with Ki of 6.66 nM. |
| PC-45839 |
GRA Ex-25
Glucagon receptor inhibitor
|
GRA Ex-25 is a potent glucagon receptor inhibitor with IC50 of 56 and 55 nM for rat and human glucagon receptors. |
| PC-42112 |
Glucagon receptor antagonist 1
|
Glucagon receptor antagonist 1 is a highly potent glucagon receptor antagonist. |
| PC-45758 |
PF-06291874
Glucagon receptor antagonist
|
PF-06291874 (PF-6291874) is a highly potent glucagon receptor antagonist with Ki of 14 nM for hGCGR. |
| PC-28525 |
Relsipatide
GIP/GLP-1 agonist
|
Relsipatide (BG128, BGM0504) is a potent, dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. |
| PC-28522 |
Zantrutide
GCGR/GIP/GLP-1 agonist
|
Zantrutide is a potent triple agonist of glucagon (GCGR), gastric inhibitory peptide (GIP), and glucagon-like peptide-1 (GLP-1) receptor. |
| PC-28519 |
Poterepatide
GLP-1/GIP agonist
|
Poterepatide (HDM1005) is a highly potent, long-acting GLP-1R/GIPR peptide dual peptide agonist. |
| PC-28512 |
Linvixdutide
GLP-1 agonist
|
Linvixdutide is a potent, selective GLP-1 receptor (GLP-1R) agonist with anti-obesity effects. |
| PC-28508 |
Brenipatide
GIP/GLP-1 agonist
|
Brenipatide (LY-3537031) is a potent, dual-agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, targets central nervous system and inflammatory pathways that include receptors linked to reward and addiction in the brain. |
